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Abstract: Epidemiological findings indicate a connection between depressive symptoms and changes in status of the im-
mune system in depressed patients. This raises the possibility of causative connections. Theories on mechanisms for inter-
actions between immune and affective systems – directly and via endocrine system – are evolving. Such hypothesized 
causative connections are supported by several findings. First, in depressed patients changes in the status of the immune 
system in vivo and ex vivo are seen. Also, depressive symptoms are seen in patients with altered immune status (physio-
logically, pathologically or chemically induced). Knowledge in this field may have implications regarding psychiatric fol-
low up of physically ill people suffering from diseases caused by an altered immune system (long lasting infections, auto-
immune diseases, hypersensitivity disorders) as well as disorders for which treatment and prognoses depends on the im-
mune system (infections, cancer). Similarly, medical treatment of depressed patients may be adjusted by more specific 
knowledge about the interaction between neuroimmunology and depression. Important findings and the present knowl-
edge and theories are reviewed.  
Keywords: Depression, immunology, endocrinology, neurology, inflammation, brain, psychiatry. 
INTRODUCTION 
 Depression is a potentially devastating disorder that can 
have profound influences on both patient and surroundings. 
While Freud attributed depression to losses in ones life, 
modern biology introduced pharmacological treatment af-
fecting the monoamine system (TCA, SSRI / SNRI, MAO-
I), indicating that depression could be a disorder with major 
disturbances in the neurotransmitter system. It has also been 
suggested that endocrine disturbances, such as hypercorti-
solemia, may be linked to depression [1] as an increase in 
level of cortisol is found in 30 – 50% of depressed patients 
[2]. As cortisol affects inflammation, there may be an impor-
tant link between inflammation and depression. However, as 
we will show in this review, recent research indicates that 
connections between the immune system and psychiatric 
symptoms may be more specific. 
 In depression, there is a changed emotional state, loss of 
interest and joy and loss of energy which results in fatigue 
and reduced activity. The patient is usually exhausted even 
after small efforts. These symptoms may also be seen in pa-
tients with persistent inflammation as well as in patients re-
ceiving treatment with cytokines or other immune modula-
tors. In addition to these shared symptoms, epidemiological 
findings indicate connections between depression and im-
munological alterations. Several prominent somatic disorders 
have been connected to depression. Depression is shown to 
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be of importance in coronary artery disease (CAD) [3], and 
is a risk factor for both development and progression of such 
disease [4], and inflammation may be a common link. There 
has also been shown a high mortality rate in demented pa-
tients who have a co-morbid depression [5]. Similarly, sev-
eral diseases characterized by a change in immune status 
(e.g. rheumatoid arthritis and inflammatory bowel disease) 
are found to be worsened by psychological stress. Another 
condition with changed status of the immune system and 
depression is the puerperal phase (post-partum depression). 
These phenomena all raise the question whether – and how - 
depression is connected to these major somatic diseases. 
 In this review we shall first briefly address depressive 
symptoms in patients with somatic disorders that may in-
volve immunological and inflammatory mechanisms. We 
then turn to immune system alterations in depressed patients. 
Potential biological mechanisms will be addressed by dis-
cussing human and animal studies revealing potential basic 
mechanisms. At the end we summarize and discuss further 
questions.  
INCREASED DEPRESSION IN SOMATIC DISOR-
DERS WITH INFLAMMATION? CARDIOVASCU-
LAR DISORDER AND THE POST-PARTUM PERIOD 
 It is well known that severe illnesses like chronic infec-
tions [6, 7], autoimmune disorder, cancer, Alzheimer’s dis-
ease, and multiple sclerosis (MS) [8, 9] are often associated 
with depression.  
 Depressed older patients have a high mortality [10-12] 
and cause of death usually is heart-, vascular – or lung re-
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lated diseases. Indeed, coronary artery disorder (CAD) is 
epidemiologically related to depression, and is a risk factor 
for both development and progression of such disease [4]. 
The incidence of depression is three times higher in CAD 
patients than in the general population [13], and 20 - 50% of 
patients who die from myocardial infarction (MI) are thought 
to be significantly depressed prior to MI [14-16]. Macro-
phages, lymphocytes, cytokines, acute phase proteins and 
adhesion molecules all are of importance in the immune re-
sponse to MI. A main focus of investigation in these patients 
has been on C-reactive protein (CRP), interleukin-6 (IL-6) 
and tumor necroses factor  (TNF) [3, 17]. These inflam-
matory mediators are - as we will show in this review - also 
increased in depression. Moreover, endothelial dysfunction 
has been reported in both depressed patients [18] and pa-
tients who have been treated successfully for their depression 
[19, 20], potentially further contributing to the link between 
depression and CAD. Finally, there are many hematological 
abnormalities in depression such as signs of platelet activa-
tion that may be of concern for patients with CAD [21]. In 
addition to posing a potential bidirectional causative link 
between inflammation and depression, this potential interac-
tion should be taken into account when it comes to choosing 
medications for one or the other of these prominent disor-
ders.  
 During pregnancy and post partum, there are changes 
both in immune status and occurrence of depressive symp-
toms. To protect the fetus against spontaneous abortion 
(miscarriage), the immune system of the mother has an im-
mune tolerance for the “non-self” tissues of the developing 
baby [22, 23]. After labor, an increase in the pro-
inflammatory immune response is noted [24, 25], involving 
activation of a T cell type 1 (Th1) response which include 
increased production of interferon (INF)  and TNF [24, 
25]. This Th1- mediated “maternal immune rebalancing” is 
potentially associated with ”post partum blues” [24], a con-
dition that is found, to varying degrees, in 20-75% of the 
mothers post partum [25-27]. Post partum depression, a more 
severe form of mood change, is found in 10-15% of the 
mothers [28].  
 These two definitively somatic physiological conditions 
(i.e., CAD and post partum period) exemplify that there may 
be an increased occurrence of depression in somatic disor-
ders and that there may be a link between immunity and de-
pression. We will now turn to immunological findings in 
depressed individuals.  
DO DEPRESSED PATIENTS HAVE MORE INFLAM-
MATION THAN OTHERS? 
 The earliest studies on connections between the immune 
system and depression focused on immune suppression 
rather than inflammation, with an impaired lymphocyte func-
tion ex vivo as a major finding [29]. Similarly, a reduced 
number of Natural killer cells (NK-cells) have been reported 
in many depressed patients [30]. However, methods for 
measuring immune activity have improved greatly the last 15 
– 20 years. Over the last 10 years, focus has changed to-
wards immune activation in vivo measured as levels of in-
flammatory cytokines and other inflammatory mediators. 
There are several reports of increased levels of inflammatory 
cytokines in depressed individuals [30-32]. These apparently 
contradictory findings (suppression vs stimulation) probably 
are not mutually exclusive, as these ex vivo and in vivo find-
ings may represent different aspects or phases of the same 
phenomena. Hence, sustained immune activation in vivo may 
result in an attenuated stimulation induced response when 
immune cells from these individuals are stimulated ex vivo, 
the distinct functions of different cytokines also must be kept 
in mind. 
 In summary, there seem to be strong indications that de-
pression is linked to increased inflammatory activity. We 
will now discuss these findings in more detail and briefly 
discuss potential mechanisms for depressive effects of in-
flammation. We will look at findings in serum and then in 
cerebrospinal fluid (CSF) and CNS of depressed patients. 
SYSTEMIC TH1-DOMINATED CYTOKINE RE-
SPONSE IN DEPRESSED INDIVIDUALS 
 Several studies on depressed patients have shown in-
creased serum- or plasma levels of inflammatory markers 
such as neopterin, a general marker of mono-
cyte/mactrophage activation, primarily reflecting Th1 activa-
tion and soluble IL-2 receptors (sIL-2R). There are also sev-
eral reports of increased levels of acute phase proteins (APP) 
such as CRP and its “upstream” inducer IL-6. Activated 
monocytes or macrophages from these patients ex vivo pro-
duce increased levels of IL-1, IL-6, TNF and prostaglandin 
E2 (PGE2). Activated T cells from depressed individuals ex 
vivo have been shown to produce increased levels of IFN 
[33-40]. Increased serum levels of IFN as well in increased 
INF-/IL-4 and INF-/transforming growth factor (TGF)- 
ratio are found. Taken together, these findings indicate a Th1 
activation and an imbalance between Th1 and Th2. This im-
balance may cause a net inflammatory effect in depressed 
individuals [41]. There are several reports that the severity of 
anxiety, depression and cognitive failure seems to be related 
to level of circulating inflammatory cytokines [42, 43].  
 In depressed patients, PGE2, a potent inflammatory me-
diator, is increased in plasma [44], saliva, serum and CSF 
[45, 46]. Ex vivo studies report increased PGE2 secretion 
from lymphocytes of depressed patients compared to lym-
phocytes from healthy individuals. Also, both clinical [45, 
47] and experimental (animal) studies of depression have 
shown an increase in tissue concentration of PGE2 [44]. IL-6, 
which is also associated with depression, seems to play a 
crucial role in synthesizing this prostaglandin [48, 49], and 
PGE2 is itself a potent stimulant for IL-6 production, poten-
tially representing an inflammatory pathogenic loop that may 
be operating in depressed individuals. It has been shown that 
tricyclic antidepressants (TCAs) and selective serotonin re-
uptake inhibitors (SSRIs) attenuate the PGE2-synthesis, 
probably via inhibition of pro-inflammatory cytokines. Fi-
nally, Müller at al. (2006) [50], reported that treatment with 
a PGE2 synthesis inhibitor (i.e., cyclooxygenase 2 inhbitor / 
COX2 inhibitor) showed beneficial effects on depression. 
All these findings indicate a potential causative link between 
PGE2 and depression.  
 Another interesting finding in depressed patients are the 
increased serum titers of antibodies against serotonin [51] 
and gangliosides (a part of the serotonin receptor) [51]. The 
presence of such antibodies is associated with increased im-
mune activation with increased levels of IL-6 and positive 
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acute phase protein (pAPP) [51]. Such reactions may indi-
cate an autoimmune reaction towards certain components in 
the serotonin system in depressed patients [32], potentially, 
at least in part, driven by Th1 related cytokines such as IL-6. 
ENHANCED ENDOTHELIAL CELL ACTIVATION IN 
DEPRESSION 
 Enhanced endothelial activation is essential in immune 
responses, to direct immune cells to relevant tissue / body 
areas. Several findings indicate an inappropriate and en-
hanced activation of the endothelium in depression. Intercel-
lular adhesion molecule-1 (ICAM-1), at least partly derived 
from endothelial cells, has been shown to be increased in 
prefrontal cortex in older depressed patients [52]. Raised 
systemic levels of the endothelial-derived E-selectin and 
vascular cell adhesion molecule-1 (VCAM-1) also have been 
reported in depression. Increased levels of nitric oxid (NO) 
may further suggest endothelial activation in these individu-
als. Endothelial activation is accompanied by increased lev-
els of chemokines such as monocyte chemo attractant pro-
tein-1 (MCP-1) that attracts leukocytes into areas of inflam-
mation. It is tempting to hypothesize that this enhanced acti-
vation of endothelial cells and chemokines could contribute 
to a disturbed blood-brain-barrier (BBB) during depression, 
potentially promoting some degree of invasion of immune 
cells into the CNS, and eventually leading to an inflamma-
tory intra-CNS response [53]. 
 To summarize, in serum from depressed patients in-
creased levels of pro-inflammatory activity is suggested 
from the finding of increased levels of pro-inflammatory 
cytokines IL1, IL-6, TNF, IFN and PGE2 in different in 
vivo studies measuring levels of serum cytokines as well as 
ex vivo studies on leucocytes from blood & serum of de-
pressed individuals. The activity seems mainly to be Th1 
dominated. In addition, antibodies against central compo-
nents traditionally thought to be important in depression (se-
rotonin) may be found, further indicating inflammatory 
processes in depression. Finally, molecules indicating endo-
thelial activation, indirectly suggesting inflammatory activa-
tion, are also increased in depressed individuals. 
INFLAMMATION IN CSF AND CNS IN DEPRESSED 
INDIVIDUALS 
 Published studies on levels of cytokines in CSF are 
sparse and to some degree contradictory. One study found 
that depressed patients had higher CSF concentrations of IL-
1, lower IL-6 and no change in TNF compared to normal 
controls [54]. Stübner et al., [55] confirmed the decreased 
level of IL-6 and also of soluble IL-6 receptor, this time in 
geriatric patients with major depression. There are also some 
reports of increased PGE2 in CSF during depression [45]. In 
contrast to these significant findings, Carpenter et al. [56] 
found no difference in levels of IL-6 in CSF in patients with 
unipolar depression compared to healthy controls, and 
Blasko et al., (2005) [57] found no elevation of TNF, TGF-
1, or MCP-1 in CSF.  
 Interpretation of these findings is difficult, and because 
of limited data, no definitive conclusions can be drawn. One 
might possibly expect levels of IL-6 to be increased in CSF, 
as they are in serum of depressed patients, especially as the 
increased levels of IL-6 seem to be associated with depres-
sive symptoms; symptoms expected to be produced in CNS. 
Several non-mutually exclusive factors may explain these 
apparently discrepant results, such as unreliable methods of 
measuring IL-6 in CSF, compartmentalization or binding of 
IL-6 in CNS or increased metabolization and removal of IL-
6 from CSF/CNS. Alternatively, depressive symptoms in 
response to – or associated with – IL-6 may reflect IL-6-
inducing effects outside CNS, affecting production or release 
of other cytokines and neurotransmitters which are conse-
quently transported into CSF/CNS, inducing depressive 
symptoms. It is tempting to hypothesize that the association 
between serum levels of IL-6 and depressive symptoms re-
flect an association between systemic inflammation and 
these symptoms, and not a direct pathogenic effect of IL-6 in 
the development of depression.  
 Glial abnormalities (in the frontal cortex) are apparent 
and consistent characteristics of major depressive disorders 
[58-61]. Miller and O`Callaghan (2005) [62] suggest that 
oligodendroglia in particular may play at part in the etiology 
of depression. They also point out that cytokines like TNF 
and IL-2 have a suppressive or cytotoxic effect on oligoden-
droglia [62], again indicating an inflammatory effect on de-
pression. 
 To summarize, in serum from depressed patients in-
creased IL-6, IL-1 and TNF cytokine levels are found, 
corresponding with at Th1-dominated pro-inflammatory re-
sponse in serum. Increased levels of PGE2 are also found. 
Antibodies against proteins related to depression have been 
shown, as well as signs of endothelial activation. Findings in 
CSF so far are less convincing, though not totally negative. 
A possibility of compartmentalization and degradation in 
CSF also has to be taken into account. Inflammation outside 
CNS modulating affective symptoms also must be explored. 
Known changes in glial cells may potentially be linked to 
inflammation.  
DOES INFLAMMATION LEAD TO DEPRESSIVE 
SYMPTOMS? FINDINGS IN HUMANS INDICATING 
A CAUSATIVE CONNECTION 
 We above have discussed evidence that depressed pa-
tients have alterations in their immune system. Whether de-
pression causes these immune changes or vise versa is not 
obvious. It is possible that inflammation may actually cause 
the depressive symptoms [63]. There are studies showing 
that changes in immune regulation often can be detected 
before the clinical symptoms of depression [8, 9, 64, 65]. 
Also, several studies have shown that administration of cer-
tain cytokines may elicit depressive symptoms in people. 
Cytokines are used in the treatment of several infectious and 
malignant disorders; for example, IFN in hepatitis C (HCV) 
and cancer, IFN in multiple sclerosis (MS), IFN in Ka-
posis sarcoma, and IL-2 in certain forms of cancer. Therapy 
with these inflammatory cytokines has been shown to be 
followed by development of depressions, manias and bipolar 
syndromes [66-68]. Importantly, patients with no prior his-
tory of mental illness have - after treatment with cytokines - 
developed depressive symptoms such as sadness, increased 
worrying, cognitive impairment, lack of motivation and dif-
ficulties with flexible thinking [32]. In patients treated with 
IFN, an increased level of soluble ICAM-1 - indicating 
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endothelial activation - has been observed to be associated 
with increased depressive symptoms [71]. Vaccination is 
known to enhance immune responses, and interestingly, vac-
cination against influenza virus in older adults has been 
shown to be associated with depressive symptoms in some 
sub-groups, and is accompanied by a rise in serum levels of 
IL-6 [77]. 
 IL-1 mediates fever in inflammation, but at the same time 
it may lead to depressive symptoms like fatigue, sadness, 
pain, emotional changes, suicidal thoughts and anorexia [69]. 
IFN and IL-2 are other cytokines mediating both inflamma-
tion and depressive symptoms of sickness behavior. Antide-
pressant medications can prevent several of the depressive 
symptoms (e.g., sadness) induced by these cytokines, but not 
the fever, anorexia and fatigue [70].  
 Another interesting approach to the question of whether 
inflammation has a causative effect, or at least a contributing 
role, in the development of depression is studying the effect 
of anti depressive medications on inflammatory markers.  
 In vitro-studies have shown that anti depressive drugs 
such as clomipramine, imipramine and citalopram attenuate 
the production of IL-1, TNF and IL-6 [32, 72]. Drugs like 
clomipramine and sertraline may therefore have an anti-
inflammatory effect [72]. A down regulation of IL-6 produc-
tion was observed after amitriptyline treatment in depressive 
patients, and in medication responders, levels of TNF were 
normalized [73]. In one in vitro study both tricyclic anti-
depressants (TCA) and selective serotonin reuptake inhibi-
tors (SSRI) impaired cytokine-induced production of PGE2 
and NO [74]. Hestad et al. (2003) [75] compared patients 
with severe depression who were given electroconvulsive 
therapy (ECT) with other severely depressed patients treated 
with other standard approaches. Compared to healthy blood 
donors, depressed patients had significantly elevated levels 
of TNF. After ECT, as depressive symptoms improved, 
TNF levels were normalized, suggesting an attenuation of 
TNF production or release after ECT.  
 Based on the discussed findings regarding immune re-
sponses and depression, it may be that the immune system 
changes induced by both anti-depressant medications [76] 
and by ECT [75], represent a common, important aspect of 
their antidepressive effect. This again would indicate in-
flammation as a mediator or cause of depression.  
EXPERIMENTS IN HUMANS  
Microbial Stimulation of the Immune System and De-
pressive Symptoms 
 In line with the findings indicating a potential causative 
effect of inflammation on depression, experimental induction 
of inflammation in healthy humans has been performed. In-
jection of a vaccine containing Salmonella (typhi or abortus) 
into human healthy volunteers leads to activation of the im-
mune system. Randomised groups injected with either Sal-
monella or placebos were monitored several times during the 
hours following injection. Monitoring consisted of psycho-
logical questionnaires, neuropsychological tests, measure-
ment of rectal temperature and heart rate; blood samples 
were taken and analyzed for cortisol and several cytokines, 
such as IL-1, IL-6 and TNF. The conclusion from several 
such experiments seems to be that, although there was a 
slight increase in rectal temperature, there was no general 
feeling of physical illness related to the injection. However, 
in some of the studies depressive effects were seen in indi-
viduals already under long standing stress. Moreover, in 
those who developed depressive symptoms, anxiety or de-
creased memory, these symptoms corresponded to increased 
levels of cortisol and inflammatory cytokines TNF, IL-1 
and IL-6 [78-80].  
Animal Models 
 Though animals do not report feelings of depression or 
existential problems typical of depression, they can inhibit 
several signs typical of depression. This includes psychomo-
tor retardation and anorexia. In addition, levels of cytokines 
can be measured, and levels and localization of neurotrans-
mitters can be monitored more systematically. In an animal 
model such depression-like symptoms following an immune 
response have been shown to be reduced by pretreatment 
with cytokine synthesis inhibitors and cytokine antagonists, 
or with cytokine gene manipulation (e.g. gene knockout) [8, 
81, 82]. In animal studies using antidepressive medications 
affecting the monoamine system there also are interesting 
findings. Proinflammatory cytokines are seems to be reduced 
upon administration of SSRI medications [83-85]. In animal 
experiments many antidepressants seem to contribute to the 
transition from a Th1 to a Th2 cytokine profile, that is, from 
a pro-inflammatory to an anti-inflammatory immune re-
sponse. In line with this, sertraline, clomipramine and tra-
zodone are in vitro observed to reduce INF-/ IL-10 ratio. 
The drugs induced both a decline in production of INF- and 
a significantly increase in production of IL-10 [86]. These in 
vitro experiments on antidepressants are consistent with the 
hypothesis that depression is associated with, and potentially 
caused by, inflammatory activity.  
Conflicting Findings? Pro-Inflammatory Activity and 
Reduced Depressive Symptoms? 
 We have reviewed research indications that depressive 
symptoms are associated with – and potentially caused by – 
pro-inflammatory cytokines. Before we discuss potential 
mechanisms we must mention potentially conflicting find-
ings. Depression is associated with change in dopaminergic 
(DA), noradrenergic (NA) and serotonergic (5-HT) activity 
in the brain. In an animal experimental system, intra-cerebro-
ventricular (i.c.v.) administration of IL-1ß was followed by 
increased hippocampal extracellular 5-HT concentrations 
[87]. In this experiment, systemic administration of cytoki-
nes (IL-1) or agents inducing production of cytokines 
(lipopolysaccarides [LPS]) showed similar effects. In ro-
dents, IL-1 has been shown to induce increased DA, NA and 
5-HT activity in hypothalamus, nucleus accumbens and lim-
bic regions, including hippocampus [86;88-90]. Administra-
tion of LPS intraperitoneally (i.p.) has been shown to in-
crease hippocampal NA and 5-HT concentrations [87, 91]. 
The LPS-induced increase in neurotransmitters was signifi-
cantly reduced if IL-1 was blocked by i.c.v. pre-treatment 
with IL-1 receptor antagonist (IL-1Ra), supporting the indi-
cations that the effect is mediated by IL-1. These findings 
strongly support theories regarding connections between the 
immune system and affective symptoms generated in the 
limbic system, potentially mediated by inflammatory cytoki-
nes.  
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 These findings may, however, be confusing as they indi-
cate that proinflammatory cytokines (directly administered 
or induced by for example administered LPS) cause increase 
in intracerebral neurotransmitters NA, 5-HT and DA. This is 
not in line with other theories regarding depression, as phar-
macological treatment of depression is mainly based on in-
creasing the presence of 5-HT and NA and even dopamine 
(bupropionhydrocloride) in synapses, indicating that de-
pressed patients have too low levels of these. One explana-
tion of this contradiction may be that the measured levels of 
neurotransmittors reflect levels outside and not within syn-
apses. Another explanation could be that there is an in-
creased turnover of these neurotransmitters, which in the 
long term will result in a deficiency.  
 Inefficient re-uptake of neurotransmitters may result in  
increased secretion due to reduced effectiveness or reduced 
number of post-synaptic receptors. 
 Another apparently conflicting finding in humans is the 
suggestion that physical activity may have a positive effect 
on depressive symptoms, but at the same time enhance the 
production of the pro-inflammatory cytokine IL-6. For ex-
ample IL-6 induce CRP and subsequent activation of the 
complement system with further inflammatory activity [92-
94]. However, the increase of IL-6 may be very temporary 
and it is actually seen that it is followed by a raise in anti-
inflammatory cytokine IL-1Ra, IL-10 and sTNFR [95, 96], 
and after repeated physical activity (for weeks or months) 
there is a decrease in levels of inflammatory cytokines.  
WHAT ARE THE POTENTIAL MECHANISMS ME-
DIATING THE CONNECTION BETWEEN DEPRES-
SION AND INFLAMMATION? 
How do Cytokines Communicate with the Brain? 
 Animal model studies have helped us to understand the 
communication between signals of systemic inflammation 
and the responses within CNS, as well as how the brain in-
ternally responds to cytokine activation. These interactions 
seem to be bidirectional, with redundant possible pathways, 
both neuronal and humoral [69].  
 Peripherally circulating cytokines may enter the brain 
and affect it by different routes. As part of an inflammatory 
process with potential upregulation of transporter molecules, 
cytokines can be transported actively across the BBB [97, 
98]. Cytokines might also be passively transported via the 
circumventral organs, especially organum vasculosum, 
where the BBB is absent [99]. Additionaly, cytokines in cir-
culation may adhere outside the BBB to the cerebral vascular 
endothelium, that is activated due to inflammation, and in-
duce second messenger systems such as prostaglandins and 
NO [30] inside the CNS. 
 Another route for the effect of peripheral cytokines on 
CNS is via afferent peripheral nerves, stimulating them pe-
ripherally with subsequent responses in the brain. The cyto-
kine effect on the vagus nerve system is an example of this 
mechanisms, as well as an example of the reciprocal interac-
tion between cytokines and the nervous system. Cortex, hy-
pothalamus and peripheral sites all project fibers to vagal 
nuclei. The vagus nerve will respond to either mechanical or 
chemical stimuli in these areas. Emotional and cognitive 
processes in cortex and subcortical structures may activate 
the vagus and those cortical and subcortical areas themselves 
receive afferent nerve-fibers from vagal nuclei. ACTH af-
fects vagal activity, and either directly or indirectly, factors 
like physical activity and fatty acids in diet may also affect 
vagal activity. In addition to fibers projecting into the CNS, a 
main effect of the vagus nerve is via neurons using acetyl-
choline (Ach) as transmitter, binding to postsynaptic 
nicotinergic/muscarinergic receptors. Medications or drugs 
stimulating or antagonizing Ach, as well as nicotine from 
tobacco, may mediate similar effects. Thus, stimulation of 
the vagus nerve by cytokines that bind to peripheral afferent 
fibers, may activate projections to hypothalamus and cortex, 
and thereby influence emotions and affect. On the other 
hand, the described Ach-receptors are present on macro-
phages and lymphocytes, so vagus activation may more di-
rectly modulate inflammation. Especially macrophages and 
lymphocytes in the spleen are reached by efferent vagal fi-
bers. An 7-subunit of the AchR seems to be specially im-
portant in mediating suppression of cytokine synthesis. This 
suppression involves JAK2 and STAT3 resulting in suppres-
sion of NF-B. In particular, the pro-inflammatory cytokines 
TNF, IL-1, IL-6 and IL-8 are all suppressed by Ach stimu-
lation. Thus, affective processes in cortex and subcortical 
areas can stimulate the vagus nerve and modulate inflamma-
tory activity [100-113]. Interestingly, actual stimulation of 
the vagus nerve, mechanically or electrically, has shown 
some positive effect in the treatment of depression [114, 
115] and it is conceivable that this could involve anti-
inflammatory effects.  
 The vagus nerve also interacts with the HPA-axes, at 
least in part by influencing the corticotrophic release factor 
(CRF) and ACTH, both coordinating the production of corti-
sol. Activity in the vagus nerve may lead to increased release 
of CRF. The close relationship between vagal nuclei, central 
areas in HPA-axes and subcortical areas involved in depres-
sion and other emotional phenomena allows for extensive bi-
directional communication among these structures. Moreo-
ver, the vagus nerve; potentially via HPA-axes, is affected 
by dietary fatty acids. This could also be a link partly ex-
plaining epidemiological connections between dietary fatty 
acids and depression.  
HPA-Axes 
 The HPA axes represent a system important in both de-
pression and inflammation. Normally, inflammation, physi-
cal stress, and psychological stress all lead to increased pro-
duction of CRH from hypothalamus. This again induces re-
lease of ACTH and Arginine vasopressin from the pituitary 
gland, stimulating the release of corticosteroids from the 
adrenal cortex. Normally, circulating corticosteroids will 
down-regulate production of CRH. In addition, there is a 
background diurnal pattern of secretion in this system, with 
lowest levels late at night. The system has well known ef-
fects on cell metabolism, anti-inflammatory effects, and also 
regulates sleep / awake cycles, food intake, and has effects 
on cognitive processes including attention and learning. 
 In depressed individuals, the background production of 
corticosteroids is increased, and diurnal variations are at-
tenuated, resulting in a more constantly increased level. In 
addition, reflexive regulation of the HPA-axes, as measured 
by the Dexamethasone Suppression Test (DMT), is reduced 
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in depressed patients. It is well recognised that administra-
tion of steroids like prednisolone (particularly in high doses), 
can cause affective symptoms. These findings are not sur-
prising as the brain areas involved in the HPA-axes project 
neurons to amygdala, raphe nucleus, nucleus ceruleus [116]- 
brain areas involved in affect and emotions, and where re-
ceptors for CRH and corticosteroids are found. Also, CRF 
acts on locus ceruleus and raphe nuclei and regulates produc-
tion of NA, a transmitter thought to be of importance in de-
pression [113]. Further supporting a link between depression 
and HPA-axes dysfunction are the findings that high circu-
lating levels of cortisol reduce the number of post-synaptic 
5-HT1A-receptors, consistent with increased depressive sym-
ptoms [117]. On the other hand, short pulses of increased 
corticosteroids may up-regulate somatodendritic levels of 5-
HT1A-receptors in a way potentially protecting against de-
pression [118-120], and short term infusion of high doses of 
corticosteroids may result in hypomania, not depression. 
Animal models have also supported theories of the involve-
ment of the HPA-axes in depression. In rodents administra-
tion of pro-inflammatory cytokines (IL-1, IL-6 and TNF) 
causes activation of the HPA-axis [90, 121-123], and this 
communication between the immune system and HPA axis 
may indeed be an important pathway in the interaction be-
tween depression and the immune system.  
 It is well recognised, and widely used therapeutically, 
that the immune system is regulated by the HPA-system, 
with potent anti-inflammatory effects of corticosteroids in-
volving down-regulation of neutrophil, macrophage and Th1 
activity. Consistant with this the HPA-axes is a regulator of 
the immune system, the immune system itself may enhance 
HPA activity when appropriate. Potent inflammatory cytoki-
nes such as TNF, IL-1 and IL-6 all bind to receptors in the 
hypothalamus, pituitary gland and adrenal glands, and up-
regulate activity in the HPA-axes. In longstanding, ongoing 
inflammations, chronic infections and autoimmune reactions, 
the immune activity may finally result in a dysregulated 
HPA-axes, as has been reported in inflammatory bowel dis-
ease (IBD) [124] and infection with human immunodefi-
ciency virus (HIV) [125]. 
 Thus, the HPA-axes regulate both the affective and the 
immune systems, and may be an important candidate in de-
lineating the mechanism for interaction between immune 
system and depression. Its role is further emphasized by the 
close connections to the cholinergic vagus nerve system. 
This can explain how affective disorders affect the immune 
system, and it could explain how inflammation, via cytoki-
nes, can activate – and potentially dysregulate – the HPA-
axes, which can again cause affective symptoms such as de-
pression.  
IDO and TDO 
 Another potential mechanism mediating immune effects 
on depression is via Indoleamin-2,3-dioxygenase (IDO) and 
tryptophan-2,3-dioxygenase (TDO). IDO and TDO are en-
zymes that are induced by several inflammatory cytokines, 
such as IL-1, IL-2, IL-6 and IFN. The substrate for IDO and 
TDO is tryptophan (TRP) and the metabolic product is 
kynurenin [126]. Thus, as inflammation leads to increased 
levels of IDO and TDO, more TRP is used by IDO and TDO 
to produce higher levels of kynurenin. Consequently, less 
TRP is available for the tryptophan hydroxylase using TRP 
as a substrate for production of serotonin. Thus, increased 
activity in IDO and TDO, result in less production of sero-
tonin [127, 128, 130, 131]. As depression is linked to mono-
amines (medications for treatment of depression affect 
monoamine systems) like serotonin and noradrenalin, there 
seems to be a lack of regulation in NA and 5-HT neuro-
transmission in depression [50, 132-140]. 
 In addition to reducing levels of serotonin, it is proposed 
that IDO and TDO can mediate depression via their meta-
bolic products. IDO and TDO turn TRP into kynurenin. 
Kynurenin metabolites 3-hydroxy-kynurenine (3OH-KYN) 
and quinoline acid (QUIN) are produced in astrocytes and 
glial cells [141, 142]. 3OH-KYN and QUIN both are neuro-
toxic and have been proposed as possibly involved in a num-
ber of neurodegenerative conditions, such as Parkinson’s 
disease and HIV-related dementia [129, 137, 143]. 3OH-
KYN may cause high production of reactive oxygen species 
(ROS), as well as an increase of monoamine oxidase (MAO) 
activity [144]. Too much ROS may negatively influence 
function or density of both serotonine and catecholamine 
receptors by inducing changes in membrane viscosity, as 
well as apoptosis [144]. Increased MAO activity is associ-
ated with depression, as increased MAO activity results in 
decreased concentrations of 5-HT and catecholamine. Inhibi-
tion of MAO is the physiological therapeutic effect of a 
group of efficient antidepressants - the MAO-inhibitors. 
 The other main IDO- / TDO byproduct, QUIN, - a potent 
NMDA-receptor agonist that may impair the physiological 
negative feedback regulation on HPA-axes - normally medi-
ated by circulating corticosteroids. QUIN neurotoxicity is 
hypothesized to cause hippocampal atrophy and loss of cor-
ticosteroid-receptors [4, 137].  
 To summarize, IDO and TDO, induced by inflammatory 
cytokines, may induce reduced monoamine neurotransmit-
tors levels by reducing bioavailability of its precursor TRP, 
by increasing degradation by MAO in response to increased 
3OH-KYN levels, and by altering the density of monoamine 
surface receptors. Products of IDO / TDO (i.e., 3OH-KYN 
and QUIN) may also have neurotoxic neurodegenerative 
effects. Activation of IDO may impair the physiological 
regulation of HPA-axes, as seen in depression. Other routes 
than IDO / TDO proinflammatory cytokines may also be 
involved in changes in NA and 5-HT. Inflammatory cytoki-
nes may directly affect 5-HT turnover (reuptake and degra-
dation) as well as receptor distribution and sensitivity in 
brain regions presumed to be involved in depression such as 
hypothalamus, hippocampus, amygdala and prefrontal cortex 
[123, 145-149], reinforcing the IDO / TDO mediated effect 
on serotonin.  
CONCLUDING REMARKS 
 This paper summarises evidence supporting basic asso-
ciations and potential causative mechanisms for inflamma-
tion to induce or modulate depressive symptoms. Future re-
search should more precisely define the most important fac-
tors - as well as their mechanism of action - in this patho-
genic loop between neurotransmittors, HPA axis and the 
immune system. Studies should also address how psycho-
logical stress affects inflammation and the potential role of 
this interaction in inflammatory disorders; and whether there 
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is a role for anti-inflammatory or immunomodulating drugs 
in the pharmacological management of depressed individu-
als.  
 Can depressive symptoms be treated by immune modu-
lating medications? As reviewed by Watson and Young 
[116], at least inflammation suppression by ketoconazole or 
mifeprisrone, as well as CRH-antagonists, can treat depres-
sive symptoms. As a basis for these additional studies, re-
search must address the primary question: can inflammation 
– caused by infection, autoimmunity or other stimulus – 
cause depression? If so, it will have major influence on pro-
phylaxis and treatment of these disorders. 
 The use of anti-inflammatory drugs in the treatment of 
depression is still only in the experimental stage [150-152]. 
Tyring et al. [153] found that etanercept (inhibiting / block-
ing binding of TNF to its receptor) treatment might relieve 
fatigue and symptoms of depression associated with in pso-
riasis. Müller et al. [154] found that celecoxib (COX-2 in-
hibitor, inhibiting production of PGE2), as an add-on medica-
tion, had therapeutic effects on major depression. Infliximab 
(blocking TNF) in the treatment of Chrons disease, has been 
reported to increase quality of life, the patient’s ability to 
work and involvement in leisure activities, and reduce feel-
ing of fatigue, anger and depression [155]. However, animal 
research has shown that many types of anti-inflammatory 
drugs may have unfortunate side effects [152]. Side effects, 
unfortunately, remain a big issue in most medications for 
treatment of depression. Through this review we have shown 
that depression is related to inflammation, but there is still a 
lot to learn before the relationship is totally understood. The 
immune system has been conceptualized as a “sixth sense” 
[156] where it may internally sense and detect things the 
body cannot otherwise hear, see, smell, taste or touch. The 
body may react to both physical and psychological stress, but 
in which way the immune system is activated as a sense is 
poorly understood in other contexts than inflammation. New 
research may enlighten our understanding and way of think-
ing about psychological reactions, and how psychological 
reactions intervene with illnesses and diseases. 
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ABBREVIATIONS 
Ach = Acetylcholine 
APP = Acute phase proteins 
ACTH = Adrenocorticotropic hormone 
ANS = Autonomic nervous system 
BBB = Blood brain barrier 
CNS = Central nervous system 
CVO = Circumventricular organs 
CAAs = Competing amino acids 
CAD = Coronar artery disease 
CRF = Corticotropin-releasing-faktor 
CS = Cortisol 
CRP = C-reactive protein 
DMT = Dexametasone suppression test 
DA = Dopamine 
ECT = Electroconvulsive treatment 
GnRH = Gonadotropin-releasing hormone 
HPA-axes = Hypothalamic, pituitary, adrenal axis 
IDO = Indoleamin-2,3-dioxygenase 
ICAM = Intercellular adhesion molecule 
IFN = Interferon 
IL = Interleukin 
LNAAs = Large Neutral amino acids 
LPS = Lipopolysaccharide 
MAO = Monoamine oxidase 
MCP = Monocyte chemo attractant protein 
MS = Multiple sclerosis 
MI = Myocardial infarction 
NK-cells = Natural killer cells 
NO = Nitric oxide 
NMDA = N-methyl-D-asparate 
NA = Noradrenalin 
PAMP = Pathogen associated molecules 
PGE = Prostaglandin E 
ROS = Reactive oxygen species 
RA = Rheumatoid arthritis 
SSRI = Selective serotonin reuptake inhibitor 
5-HT = Serotonin 
SNRI = Serotonin noradrenaline reuptake inhibitor /- 
Selective serotonin and noradrenalin reuptake 
inhibitor 
Th-cells = T-helper cells 
TLRs = Toll-like receptors 
TGF = Transforming growth factor 
TCA = Tricyclic antidepressants 
TRP = Tryptophan 
TDO = Tryptophan-2,3-dioxygenase 
TNF = Tumor necrosis factor 
VCAM-1 = Vascular cell adhesion molecule-1 
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